GENE ONLINE|News &
Supernus Invests $400 Million to Acquire New Parkinson’s Assets from Adamas
On October 11th, Maryland-based Supernus Pharmaceuticals announced that it is acquiring Adamas Pharmaceuticals in an all-cash deal amounting to approximately $400 million. This roughly comes out to $9.10 per share, which includes an upfront payment of $8.10 per share.
An additional $1.00 contingent value right will be paid if Adamas' top-selling Parkinson's drug, Gocovri, achieves certain sales milestones. Specifically, the first CVR worth $0.50 per share, is payable if net sales touch $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR is payable if the drug makes $225 million in any four consecutive quarters between closing and the end of 2025.
An additional $1.00 contingent value right will be paid if Adamas' top-selling Parkinson's drug, Gocovri, achieves certain sales milestones. Specifically, the first CVR worth $0.50 per share, is payable if net sales touch $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR is payable if the drug makes $225 million in any four consecutive quarters between closing and the end of 2025.
GO Prime with only $1.49 now
LATEST
Forced Migrants in Ukraine Face Barriers to HIV and TB Care Amid Disrupted Healthcare Systems
2026-01-23
Residual Cardiovascular Risk Persists in Coronary Artery Disease Despite Advances in Treatment
2026-01-23
Advocacy-Informed Research and PRISM Framework Highlighted in Healthcare Policy Reform Strategies
2026-01-23
Study Explores Link Between Red Blood Cell Distribution Width and Prognosis in Peripheral T-Cell Lymphoma
2026-01-23
